NICOX SA EUR1 (NASDAQ:NICXF) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Tuesday.

According to Zacks, “Nicox is an international commercial-stage company focused on the ophthalmic market. With a heritage of innovative R&D, business development and marketing expertise, they are building a diversified portfolio of ophthalmic products that can help people to enhance their sight. Nicox’s advanced pipeline features two pre-NDA candidates (Vesneo for glaucoma, partnered with Bausch + Lomb / Valeant and AC-170 for allergic conjunctivitis) as well as two pre-MAA candidates (AzaSite for bacterial conjunctivitis and BromSite for pain and inflammation after cataract surgery). The Group operates directly in six countries, including the United States. It has proprietary commercial operations in Europe’s five largest markets complemented by an expanding international network of distributors. Nicox is headquartered in France and has more than 120 staff worldwide. It is listed on Euronext Paris (Category B: Mid Caps) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. “

NICOX SA EUR1 (NASDAQ:NICXF) traded down 6.051% on Tuesday, reaching $9.254. The company’s stock had a trading volume of 386 shares. The stock’s 50 day moving average price is $11.22 and its 200 day moving average price is $10.97. NICOX SA EUR1 has a 52-week low of $1.69 and a 52-week high of $14.75. The firm’s market cap is $211.44 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

5 Day Chart for NASDAQ:NICXF

Get a free copy of the Zacks research report on NICOX SA EUR1 (NICXF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for NICOX SA EUR1 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NICOX SA EUR1 and related companies with's FREE daily email newsletter.